Technical Analysis for GRFS - Grifols, S.A.

Grade Last Price % Change Price Change
F 6.05 -1.31% -0.08
GRFS closed down 1.31 percent on Monday, March 18, 2024, on 59 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Reached Oversold Weakness -1.31%
Wide Bands Range Expansion -1.31%
Gapped Up Strength -1.31%
Oversold Stochastic Weakness -1.31%
Narrow Range Bar Range Contraction 5.03%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 15 hours ago
Possible Inside Day about 15 hours ago
Down 3% about 19 hours ago
Down 2 % about 19 hours ago
Down 1% about 19 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Grifols, S.A. Description

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, and Canada. It specializes in providing infusion solutions, nutrition products, medical devices, and diagnostic instrumentation and reagents for use in hospitals and clinics. The company operates in four divisions: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience division manufactures and sells plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This division offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic division focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, such as analytical instruments and reagents for diagnostics, as well as blood bank products. This division serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital division manufactures and installs products used by and in hospitals comprising parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others division engages in the sale of intermediate pastes and plasma to third parties. The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and a range of other medical conditions. The company was formerly known as Probitas Pharma, S.A. and changed its name to Grifols, S.A. in 2005. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Medicine Biopharmaceutical Infectious Diseases Clinic Healthcare Providers Antibody Hematology In Vitro Diagnostic Products Nutrition Products Blood Plasma Hemophilia Analytical Instruments Transfusion Medicine Ibex 35 In Vitro Diagnostics Derivative Products Blood Bank Bank Products Blood Donation Infusion Solutions Parenteral Nutrition Plasma Products

Is GRFS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 12.1499
52 Week Low 5.3001
Average Volume 3,511,795
200-Day Moving Average 9.07
50-Day Moving Average 7.82
20-Day Moving Average 7.29
10-Day Moving Average 6.16
Average True Range 0.56
RSI (14) 37.89
ADX 29.62
+DI 22.55
-DI 41.49
Chandelier Exit (Long, 3 ATRs) 7.68
Chandelier Exit (Short, 3 ATRs) 6.99
Upper Bollinger Bands 10.00
Lower Bollinger Band 4.58
Percent B (%b) 0.27
BandWidth 74.33
MACD Line -0.65
MACD Signal Line -0.55
MACD Histogram -0.0929
Fundamentals Value
Market Cap 4.1 Billion
Num Shares 678 Million
EPS 0.04
Price-to-Earnings (P/E) Ratio 151.25
Price-to-Sales 1.03
Price-to-Book 0.85
PEG Ratio 0.38
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.26
Resistance 3 (R3) 6.24 6.16 6.23
Resistance 2 (R2) 6.16 6.10 6.17 6.21
Resistance 1 (R1) 6.10 6.07 6.06 6.12 6.20
Pivot Point 6.02 6.02 6.00 6.03 6.02
Support 1 (S1) 5.96 5.96 5.92 5.98 5.90
Support 2 (S2) 5.88 5.93 5.89 5.89
Support 3 (S3) 5.82 5.88 5.88
Support 4 (S4) 5.84